Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax is a research paper published in Cancer (2021). On theSindex it has a DataRank of 3.9. It has been cited 158 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.760
From this paper's citation signal
Citation Network Contribution
3.2
From 98 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
National Institutes of Health
Grant: R01CA235622
American Society of Clinical Oncology
Grant: Young Investigator Award
National Cancer Institute
Grant: MD Anderson Cancer Center Support Grant CA016672
NCI NIH HHS
Grant: R01 CA231364
NCI NIH HHS
Grant: P30 CA016672
National Institutes of Health
Grant: 5R01CA235622-02
Targeting apoptosis in high-risk AML and MDS with BCL-2 inhibitor Venetoclax and optimized 10-day Decitabine regimen
FWCI
15.49
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals